Zhongsheng Pharma addresses unusual stock surge, confirms normal operations

Guangdong Zhongsheng Pharmaceutical's stock experienced abnormal fluctuations, with its closing price deviating by over 20% across three consecutive trading days from November 12 to November 14, 2025. In response, the company's board of directors, controlling shareholder, and actual controller conducted verifications. They confirmed no uncorrected or supplementary information in previous disclosures and no recent public media reports that could significantly impact the stock price. The company asserts its current operating situation is normal, with no material changes in its internal or external operating environment.

Furthermore, the company, its controlling shareholder, and actual controller confirmed the absence of any major undisclosed matters or matters in the planning stage. No trading of the company's stock by the controlling shareholder or actual controller occurred during the period of abnormal fluctuation. The company highlighted ongoing phase III clinical trials for various drug candidates, including Anglabivir for influenza and RAY1225 for obesity and type 2 diabetes, acknowledging the inherent uncertainties in drug development, approval, and commercialization.

Zhongsheng Pharmaceutical reiterated it will strictly adhere to information disclosure requirements, urging investors to exercise caution given the associated risks. The approved small molecule innovative drug Anglabivir tablet for adult influenza, a global first-in-class influenza RNA polymerase PB2 inhibitor, faces market uncertainties post-approval due to industry-specific factors, policy changes, and competition.